SCGAN:乳腺癌预测中的反事实解释的稀疏反GAN
Siqiong Zhou1, Upala J Islam1, Nicholaus Pfeiffer2
1School of Computing and Augmented Intelligence, Arizona State University.
概括
这项研究介绍了Sparse CounteRGAN (SCGAN),以了解成像,临床和分子 (ICM) 特性如何影响新辅助全身疗法 (NST) 后乳腺癌治疗反应. SCGAN生成现实,稀疏和多样化的反事实,用于因果推理.
科学领域:
- 放射学和医学成像技术
- 计算生物学和生物信息学
- 机器学习和人工智能的人工智能
背景情况:
- 来自MRI的放射性图像在预测乳腺癌治疗对新辅助全身疗法 (NST) 的反应方面表现有希望.
- 了解成像,临床和分子 (ICM) 特征和治疗反应之间的因果关系对于个性化医学至关重要.
- 现有的反事实解释方法面临着高维度,现实主义和特征混的挑战.
研究的目的:
- 提出一种新的方法,Sparse CounteRGAN (SCGAN),用于生成现实和可解释的反事实解释.
- 在接受NST的乳腺癌患者中,揭示ICM特征和治疗反应之间的因果关系.
- 为了解决现有的反事实生成技术的局限性.
主要方法:
- 开发了SCGAN,一种生成方法学习数据分布,用于实现现实的反事实实例生成.
- 为歧视者提供综合的退学培训,以强制执行反事实中的稀疏性.
- 在损失函数中引入了多样性术语,以最大化生成的反事实之间的距离.
主要成果:
- SCGAN成功地产生了稀疏和多样化的反事实实例.
- 生成的反事实证明了可信性和可行性.
- 在多个数据集上进行评估,SCGAN在揭示因果关系方面优于现有的方法.
结论:
- 在高维度医疗数据中,SCGAN为因果推理提供了有价值的工具.
- 该方法增强了对ICM特征对乳腺癌治疗反应的影响的理解.
- SCGAN促进了对乳腺癌管理的更知情的临床决策.
相关概念视频
Cancer Survival Analysis
456
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
456
Assumptions of Survival Analysis
198
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
198
Confounding in Epidemiological Studies
265
Confounding in statistical epidemiology represents a pivotal challenge, referring to the distortion in the perceived relationship between an exposure and an outcome due to the presence of a third variable, known as a confounder. This variable is associated with both the exposure and the outcome but is not a direct link in their causal chain. Its presence can lead to erroneous interpretations of the exposure's effect, either exaggerating or underestimating the true association. This...
265
Comparing the Survival Analysis of Two or More Groups
289
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
289
Cancer-Critical Genes II: Tumor Suppressor Genes
8.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.0K
Censoring Survival Data
241
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
241


